A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer

被引:58
作者
Miles, DW
Smith, IE
Coleman, RE
Calvert, AH
Lind, MJ
机构
[1] Univ Hull, Princess Royal Hosp, Sch Med, Kingston Upon Hull HU8 9HE, N Humberside, England
[2] Guys Hosp, London SE1 9RT, England
[3] Royal Marsden Hosp, London SW3 6JJ, England
[4] Weston Pk Hosp, Sheffield, S Yorkshire, England
[5] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
关键词
pemetrexed disodium; ALIMTA; LY231514; metastatic breast cancer; multitargeted antifolate; phase II;
D O I
10.1016/S0959-8049(01)00117-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A phase LT study was conducted to evaluate the activity of pemetrexed in patients with locally recurrent or metastatic breast cancer. 38 patients, median age 52 years (range 36-71 years), were given pernetrexed 600 mg/m(2) as a 10-min intravenous (i.v.) infusion every 3 weeks. Median time from diagnosis to study entry was 48 months (range 14.7-310 months). 33 of 38 patients had prior chemotherapy; 16 adjuvant, 12 metastatic and 5 in both settings. Sites of disease included skin and soft tissue (19/38) nodes (18/38), lung (17/38), liver (13/38) and bone (3/38). An overall response rate of 28% (95% confidence interval (CI): 14.2-45.2%) in 10/36 evaluable patients 1 complete response (CR), 9 partial responses (PR), included reductions in hepatic and pulmonary metasrases. 5 of 10 responders had received taxoid or anthracycline therapy for metastatic disease; 3 of these 5 had also received adjuvant chemotherapy. Median duration of response was 8 months (range 1.6-14 + months), and median survival was 13 months (95% CT 9.56-17.38 months), 167 courses were given (median five per patient; range 1-9), with 37 reductions and 33 delays. Reasons for reduction included neutropenia(11%) and mucositis (5%), with delays due to raised LFTs (21%), neutropenia (12%) and other non-treatment related events. The major haematological toxicities (Common Toxicity Criteria) (CTC) were grade 3/4 neutropenia (47%) and thrombocytopenia (15.7%) of patients. There was one report of a grade 3 infection. Non-haematological toxicities (all grades 2/3) included elevated transaminases (92%), vomiting (34%), nausea (34%) and mucositis (32%). One episode of grade 4 diarrhoea was reported. Other toxicities included a skin rash, grade 2 (42%), 3 (5%) and 4 (13%), which was ameliorated by the use; of prophylactic dexamethasone. These results suggest that pemetrexed has significant antitumour activity in advanced breast cancer with responses in patients who had previously received anthracyclines and taxoids. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1366 / 1371
页数:6
相关论文
共 28 条
[1]   Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].
Blum, JL ;
Jones, SE ;
Buzdar, AU ;
LoRusso, PM ;
Kuter, I ;
Vogel, C ;
Osterwalder, B ;
Burger, HU ;
Brown, CS ;
Griffin, T .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493
[2]   Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay [J].
Britten, CD ;
Izbicka, E ;
Hilsenbeck, S ;
Lawrence, R ;
Davidson, K ;
Cerna, C ;
Gomez, L ;
Rowinsky, EK ;
Weitman, S ;
Von Hoff, DD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (02) :105-110
[3]   ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN PLUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN THE TREATMENT OF RESECTABLE BREAST-CANCER WITH MORE THAN 3 POSITIVE AXILLARY NODES [J].
BUZZONI, R ;
BONADONNA, G ;
VALAGUSSA, P ;
ZAMBETTI, M .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2134-2140
[4]   Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells [J].
Chen, VJ ;
Bewley, JR ;
Andis, SL ;
Schultz, RM ;
Iversen, PW ;
Shih, C ;
Mendelsohn, LG ;
Seitz, DE ;
Tonkinson, JL .
BRITISH JOURNAL OF CANCER, 1998, 78 (Suppl 3) :27-34
[5]  
Clark BP, 1998, ANN ONCOL, V9, P109
[6]   Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study [J].
Cripps, C ;
Burnell, M ;
Jolivet, J ;
Batist, G ;
Lofters, W ;
Dancey, J ;
Iglesias, J ;
Fisher, B ;
Eisenhauer, EA .
ANNALS OF ONCOLOGY, 1999, 10 (10) :1175-1179
[7]   SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].
GREEN, S ;
WEISS, GR .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253
[8]  
HABECK LL, 1995, MOL PHARMACOL, V48, P326
[9]  
John W, 2000, CANCER-AM CANCER SOC, V88, P1807, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO
[10]  
2-L